modelPalbociclib

Diagram of Palbociclib

Extends from Pharmacolibrary.Drugs.ATC.L.L01EF01.

Information

name:Palbociclib
ATC code:L01EF01
route:oral
compartments:2
dosage:125mg
volume of distribution:3240L
clearance:63.3L/hr
other parameters in model implementation

Palbociclib is an oral, selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), used primarily in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is an FDA- and EMA-approved antineoplastic agent administered in combination with endocrine therapy.

Pharmacokinetics

Population pharmacokinetics in adult advanced breast cancer patients, both female and male (predominantly female), mean age ~57 years, oral dosing.

References

  1. Royer, B, et al., & Schmitt, A (2021). Population Pharmacokinetics of Palbociclib in aReal-World Situation. Pharmaceuticals (Basel, Switzerland) 14(3) –. DOI:10.3390/ph14030181 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33668400

  2. Yu, Y, et al., & Wang, D (2020). Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function. Cancer chemotherapy and pharmacology 86(6) 701–710. DOI:10.1007/s00280-020-04163-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33037918

  3. Panetta, JC, et al., & Stewart, CF (2024). Population Pharmacokinetic and Pharmacodynamic Study of Palbociclib in Children and Young Adults with Recurrent, Progressive, or Refractory Brain Tumors. Pharmaceutics 16(12) –. DOI:10.3390/pharmaceutics16121528 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39771507

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)